YOLFTbeta
Kyobo 8 Special Purpose Acquisition Company

Kyobo 8 Special Purpose Acquisition Company

307280 · KQ · Healthcare / Medical Instruments & Supplies

5,510.00KRW+280.00 (+5.35%)

Price History

Full chart

Market Stats

Previous Close5,230.00
Open5,230.00
Day Range5,170.00 – 5,670.00
52-Week Range4,669.29 – 8,400.00
Volume63.09K
Market Cap40.50B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield2.33%
Beta0.55
50-Day Avg5,896.80
200-Day Avg6,544.30

About

Wonbiogen Co., Ltd. manufactures and sells wound dressings in South Korea, rest of Asia, Europe, and internationally. It operates through Wound Dressing and Daily Necessities divisions. The company offers polyurethane foam and hydrocolloid dressings; cosmetics; other dressings; and daily necessities. It also provides medical, organic, and inorganic materials; and laundry detergents. Wonbiogen Co., Ltd. was founded in 2006 and is headquartered in Gumi-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOKim Won Il
  • Employees80
  • Headquarters56, 1Gongdan-ro 5-gil, Gumi-si, South Korea, Korea
  • Websitehttps://www.wonbiogen.co.kr

Leadership

  • Kim Won IlChief Executive Officer

Financials

Income Statement

Currency: KRW2018-12-312019-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--26.75B29.61B30.44B35.24B
Growth (%)---+10.72%+2.79%+15.78%
Cost of Revenue--14.28B15.42B16.16B17.43B
Gross Profit--12.46B14.19B14.28B17.82B
Gross Margin--46.60%47.93%46.91%50.55%
Operating Expense--7.31B7.07B7.87B9.62B
Operating Income--5.15B7.12B6.41B8.19B
Operating Margin--19.26%24.05%21.05%23.24%
EBITDA--6.14B8.84B8.13B9.33B
EBITDA Margin--22.95%29.86%26.70%26.47%
Net Income--3.21B5.50B5.69B6.62B
Net Income Margin--11.99%18.56%18.69%18.77%
R&D--492.10M504.15M838.47M723.49M
R&D as % of Total Revenue--1.84%1.70%2.75%2.05%
Interest Expense001.27B116.68M57.77M40.26M
Interest Expense % of Total Revenue--4.76%0.39%0.19%0.11%

Balance Sheet

Currency: KRW2018-12-312019-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--38.93B42.90B41.27B47.63B
Total Liabilities--12.11B10.28B4.00B5.00B
Total Equity--26.87B32.22B37.21B42.73B
Cash--3.23B3.04B7.20B8.26B
Net Debt--5.53B3.74B--

Cash Flow

Currency: KRW2018-12-312019-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-112.37M-46.61M5.78B4.84B8.85B8.48B
Investing Cash Flow-18.60B-----
Capital Expenditure006.57B1.73B664.63M2.02B
Free Cash Flow---786.11M3.10B8.18B6.46B
Dividends Paid---349.55M709.19M709.19M
FCF to OCF---13.60%64.13%92.49%76.17%
Dividend Paid to FCF---11.27%8.66%10.98%

Earnings

Report DateSep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026
EPS Estimate---------------------------
EPS Actual13.8222.11956.08-1003.51207.69-18010.58-370.4096.8475.9546.77115.47111.80212.3213.11183.24268.5875.13173.47137.72213.22184.10224.35175.19226.24307.05224.08241.09
Surprise---------------------------
Timing---------------------------

Key Statistics & Ratios

Market Cap40.50B
Enterprise Value34.03B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.07
Price / Book0.91
Revenue (TTM)37.80B
Gross Profit (TTM)19.56B
EBITDA11.16B
Profit Margin22.28%
Operating Margin27.48%
Return on Equity20.07%
Return on Assets12.31%
Shares Outstanding6.81M
Shares Float4.51M
Beta0.55
Dividend Yield2.33%
Dividend Rate140.00
Payout Ratio18.13%

Dividends

20251×
140.00Dec 29, 2025
20241×
100.00Dec 27, 2024
20231×
100.00Dec 27, 2023
20221×
50.00Dec 28, 2022

Stock Splits

  • May 26, 20251:5